9 employees
Vaxxel is an Innovative viral live-attenuated platform for intranasal vaccine candidates preventing against pneumovirus infections
2019
$1.3M
from 1 investors over 1 rounds
Vaxxel raised $1.3M on March 18, 2022
Investors: Angels Santé